Clinical Trial Update: Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of M2ES and gemcitabine in patients with advanced pancreatic cancer; sponsored by Protgen Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• M2ES

Snippet

Sponsor: Protgen Ltd | Conditions: Pancreatic Cancer | Phase 1 | Status: UNKNOWN